iwCAR-T 2022 | Exploring the potential of CAR-T therapy in CLL
Despite the initial promise of CAR-T therapy in chronic lymphocytic leukemia (CLL), clinical success has been limited so far. In this session chaired by John Gribben, MD, DSc, FRCPath, FMed Sci, Barts and The London School of Medicine, Queen Mary University of London, London, UK, Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA and Saar Gill, MD, PhD, University of Pennsylvania, Philadelphia, PA, discuss some of the barriers to CAR-T therapy in CLL, exploring the role of CAR-T therapy in CLL and debating the optimal time to use this strategy in patients. Moving forward, the experts comment on the financial advantages associated with the use of CAR-T therapy over BTK inhibitors and move on to discuss the differences between CD28 and 4-1BB CAR-T constructs, questioning the importance of CAR-T persistence in CLL. This discussion took place at the 4th International Workshop on CAR-T (iwCAR-T) 2022 held in Tampa, FL.
